Skip to main content

Catalyst Calendar

Scope

Wed, Aug 26, 2026

1 updates
NAMS
8:00 AM

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Presentation / Abstract • Phase 3ESC moderated poster presentation Fri, Aug 28, 2026, 10:15 AM CETnewamsterdampharma.com

Thu, Aug 6, 2026

1 updates

Wed, Aug 5, 2026

1 updates
NAMS
7:00 AM

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents

Presentation / Abstract • Phase 3AAIC presentation Wed, Jul 1, 2026, 9:00 AM ETnewamsterdampharma.com

Wed, Jul 29, 2026

1 updates
NAMS
8:00 AM

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

newamsterdampharma.com

Fri, Jul 24, 2026

1 updates
NAMS
8:00 AM

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data - - European Commission decision expected in 2H26 - NAARDEN, The

newamsterdampharma.com

Thu, Jul 2, 2026

1 updates

Wed, Jul 1, 2026

1 updates
NAMS
8:00 AM

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Presentation / Abstract • Phase 3AAIC oral presentation Mon, Jul 13, 2026, 9:30 AM BSTnewamsterdampharma.com

Wed, Jun 3, 2026

1 updates
NAMS
8:00 AM

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Presentation / Abstract • Phase 3NLA Scientific Sessions presentation Fri, Jun 12, 2026, 10:30 AM CDTnewamsterdampharma.com